| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00000310 Details | 2017-01-16 Interventional | 2 | - | Risperidone Cocaine-Related… | - - | |||
| NCT00812812 Details | 2017-01-13 Interventional | 4 | 56 | Paroxetine Depression Depressive Diso… | - - | |||
| NCT01221740 Details | 2017-01-12 Interventional | 3 | 0 | Levomilnacipran Milnacipran Back Pain | Company decided to discontinue - | |||
| NCT00218049 Details | 2017-01-12 Interventional | 1 | 3 | Vanoxerine Cocaine-Related… Cocaine Abuse | Issue of priority of resources - | |||
| NCT00046813 Details | 2017-01-12 Interventional | 4 | - | Nicotine Psychotic Disor… Schizophrenia Tobacco Use Dis… | Interim data analysis showed no effect between treatment groups - | |||
| NCT00000313 Details | 2017-01-12 Interventional | 1 | - | Fenfluramine Cocaine-Related… | - - | |||
| NCT02439138 Details | 2017-01-11 Interventional | 2 | 5 | Idelalisib Waldenstrom Mac… Waldenstrom's M… | Safety issues from trials in CLL This study was terminated early due to safety concerns from the previously untreated CLL experience. All participants who remained on study at that time were permanently removed from protocol therapy. The median time on protocol therapy was 1 cycle | |||
| NCT02319200 Details | 2017-01-11 Interventional | 3 | 11 | Metformin Carcinoma Carcinoma, Hepa… Fibrosis Hepatitis C Hepatitis C, Ch… Liver Cirrhosis Cirrhosis Hepatocellular … | Decision of investigator - | |||
| NCT01201538 Details | 2017-01-11 Interventional | 2 | 2 | Nilotinib Neurilemmoma Neuroma, Acoust… Growing Vestibu… | Study PI passed away We had trouble recruiting for the drug arm - | |||
| NCT01148992 Details | 2017-01-11 Interventional | 1 | 16 | Lofexidine Cocaine-Related… Cocaine Related… | - - | |||
| NCT01060865 Details | 2017-01-11 Interventional | 4 | 50 | Aliskiren Hypertension Blood Pressure,… | The participants signed an old version of the informed consent. - | |||
| NCT00090194 Details | 2017-01-11 Interventional | 2 | 56 | Antibodies Immunoglobulins Immunoglobulins… Rho(D) Immune G… gamma-Globulins Kidney Failure,… Renal Insuffici… | - - | |||
| NCT00045591 Details | 2017-01-11 Interventional | 2 | 39 | Celecoxib Breast Neoplasm… Breast Cancer | - - | |||
| NCT00000936 Details | 2017-01-11 Interventional | 3 | 292 | Cyclosporine Cyclosporins Kidney Transpla… | - - | |||
| NCT02310568 Details | 2017-01-09 Interventional | 2 | 90 | PF-06372865 Anxiety Disorde… Generalized Anx… | Study recruitment was terminated on 24 June 2015, due to a Pfizer business decision. This study
was not terminated for reasons of safety or efficacy All 34 centres who enrolled subjects were terminated due to internal sponsor portfolio prioritization. The decision to terminate the study was not due to any safety concern or change in the benefit:risk assessment of PF-06372865 | |||
| NCT01817777 Details | 2017-01-09 Interventional | 4 | 31 | Metformin Diabetes Mellit… Diabetes Mellit… | It's no longer feasible to continue to recruit patients into the study as severe recruitment
difficulties have been experienced since the study start - | |||
| NCT02213744 Details | 2017-01-06 Interventional | 2/3 | 113 | Capecitabine Gemcitabine Trastuzumab Vinorelbine Breast Neoplasm… Breast Cancer HER2 Positive B… | Felt not to show benefit over control per DMC and confirmed via futility analysis - | |||
| NCT01708798 Details | 2017-01-05 Interventional | 2/3 | 44 | Eplerenone Breast Neoplasm… Breast Cancer | Futility - | |||
| NCT01383148 Details | 2017-01-05 Interventional | 2/3 | 222 | Carboplatin Cisplatin Gemcitabine Paclitaxel Pemetrexed Carcinoma, Non-… Non-Small-Cell … | - - | |||
| NCT00663910 Details | 2017-01-02 Interventional | 1 | 18 | Aminolevulinic … Skin Neoplasms Non-melanomatou… | Of the 8 histologically proven tumors, detection of PpIX proved to be ambiguous. - |